Clinical trial
Liposomal Daunorubicin in Treating Patients With Metastatic Breast Cancer
NCT00004207 · University of Leicester, Other · Unknown status
Key facts
| NCT number | NCT00004207 |
|---|---|
| Title | Liposomal Daunorubicin in Treating Patients With Metastatic Breast Cancer |
| Official title | A Phase I Study to Determine the Maximum Tolerated Dose of Daunoxome as Therapy for the Treatment of Metastatic Breast Cancer |
| Lead sponsor | University of Leicester, Other |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | liposomal daunorubicin citrate |
| Start date | Dec 1, 1997 |
| First posted | Aug 9, 2004 |
| Last update posted | Jun 24, 2014 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: